ArticleDiscover oncology2025
Application of ultrasound-guided microwave ablation combined with polidocanol injection in benign cystic-solid thyroid nodules and recurrence analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy of thyroid cyst sclerotherapy with polidocanol.Radiology and oncology · 2026Article
- Efficacy of dual-modality ablation for symptomatic cystic thyroid nodules.Gland surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study is intended to investigate the efficacy of ultrasound-guided microwave ablation (MWA) combined with polyguinol injection in treating benign cystic-solid thyroid nodules and its effect on recurrence rates.
methodsA retrospective analysis was conducted on 120 patients with benign cystic-solid thyroid nodules, who were divided into two groups based on different treatment modalities: the control group (60 cases) and the observation group (60 cases). The control group underwent ultrasound-guided MWA combined with anhydrous ethanol sclerotherapy, while the observation group received ultrasound-guided MWA combined with polidocanol sclerotherapy. Treatment efficacy was assessed postoperatively. Serum levels of free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH)were measured before and after surgery. Changes in nodule volume and volume reduction rates were compared. The incidence of adverse reactions and recurrence rates were recorded.
resultsThe observation group demonstrated a significantly higher overall treatment efficacy compared to the control group (P < 0.05). There were no significant differences in preoperative and postoperative FT3, FT4, and TSH levels between the two groups, indicating preserved thyroid function. Postoperative thyroid nodule volumes were significantly reduced in both groups compared to pre-treatment values, with the observation group achieving greater reductions than the control group (P < 0.05). The volume reduction rate was also notably higher in the observation group (P < 0.05). Additionally, the observation group experienced a lower incidence of adverse reactions and recurrence compared to the control group (P < 0.05).
conclusionUltrasound-guided MWA combined with polidocanol injection is more effective in treating benign cystic-solid thyroid nodules. This approach accelerates nodule ablation, significantly reduces nodule size, preserves thyroid function, lowers recurrence rates, and enhances overall safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.